BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

163 related articles for article (PubMed ID: 29660315)

  • 21. Effect of simvastatin on the resistance to EGFR tyrosine kinase inhibitors in a non-small cell lung cancer with the T790M mutation of EGFR.
    Hwang KE; Kwon SJ; Kim YS; Park DS; Kim BR; Yoon KH; Jeong ET; Kim HR
    Exp Cell Res; 2014 May; 323(2):288-96. PubMed ID: 24631288
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Predictive biomarkers to tyrosine kinase inhibitors for the epidermal growth factor receptor in non-small-cell lung cancer.
    De Luca A; Normanno N
    Curr Drug Targets; 2010 Jul; 11(7):851-64. PubMed ID: 20388064
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Synergistic effects of gefitinib and thalidomide treatment on EGFR-TKI-sensitive and -resistant NSCLC.
    Xia X; Liu Y; Liao Y; Guo Z; Huang C; Zhang F; Jiang L; Wang X; Liu J; Huang H
    Eur J Pharmacol; 2019 Aug; 856():172409. PubMed ID: 31132355
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Early emergence of de novo EGFR T790M gatekeeper mutations during erlotinib treatment in PC9 non-small cell lung cancer cells.
    Kim S; Park AK; Cho J
    Biochem Biophys Res Commun; 2018 Sep; 503(2):710-714. PubMed ID: 29909007
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Overexpression of AGR2 Is Associated With Drug Resistance in Mutant Non-small Cell Lung Cancers.
    Luu TT; Bach DH; Kim D; Hu R; Park HJ; Lee SK
    Anticancer Res; 2020 Apr; 40(4):1855-1866. PubMed ID: 32234873
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Ursolic acid promotes apoptosis and mediates transcriptional suppression of CT45A2 gene expression in non-small-cell lung carcinoma harbouring EGFR T790M mutations.
    Yang K; Chen Y; Zhou J; Ma L; Shan Y; Cheng X; Wang Y; Zhang Z; Ji X; Chen L; Dai H; Zhu B; Li C; Tao Z; Hu X; Yin W
    Br J Pharmacol; 2019 Dec; 176(24):4609-4624. PubMed ID: 31322286
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Shikonin sensitizes wild‑type EGFR NSCLC cells to erlotinib and gefitinib therapy.
    Li YL; Hu X; Li QY; Wang F; Zhang B; Ding K; Tan BQ; Lin NM; Zhang C
    Mol Med Rep; 2018 Oct; 18(4):3882-3890. PubMed ID: 30106133
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Cucurbitacin B Induces the Lysosomal Degradation of EGFR and Suppresses the CIP2A/PP2A/Akt Signaling Axis in Gefitinib-Resistant Non-Small Cell Lung Cancer.
    Liu P; Xiang Y; Liu X; Zhang T; Yang R; Chen S; Xu L; Yu Q; Zhao H; Zhang L; Liu Y; Si Y
    Molecules; 2019 Feb; 24(3):. PubMed ID: 30759826
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Apatinib enhances antitumour activity of EGFR-TKIs in non-small cell lung cancer with EGFR-TKI resistance.
    Li F; Zhu T; Cao B; Wang J; Liang L
    Eur J Cancer; 2017 Oct; 84():184-192. PubMed ID: 28822888
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Primary resistance to epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors (TKIs) in patients with non-small-cell lung cancer harboring TKI-sensitive EGFR mutations: an exploratory study.
    Lee JK; Shin JY; Kim S; Lee S; Park C; Kim JY; Koh Y; Keam B; Min HS; Kim TM; Jeon YK; Kim DW; Chung DH; Heo DS; Lee SH; Kim JI
    Ann Oncol; 2013 Aug; 24(8):2080-7. PubMed ID: 23559152
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Genistein enhances the effect of epidermal growth factor receptor tyrosine kinase inhibitors and inhibits nuclear factor kappa B in nonsmall cell lung cancer cell lines.
    Gadgeel SM; Ali S; Philip PA; Wozniak A; Sarkar FH
    Cancer; 2009 May; 115(10):2165-76. PubMed ID: 19288574
    [TBL] [Abstract][Full Text] [Related]  

  • 32. An HER3-targeting antibody-drug conjugate incorporating a DNA topoisomerase I inhibitor U3-1402 conquers EGFR tyrosine kinase inhibitor-resistant NSCLC.
    Yonesaka K; Takegawa N; Watanabe S; Haratani K; Kawakami H; Sakai K; Chiba Y; Maeda N; Kagari T; Hirotani K; Nishio K; Nakagawa K
    Oncogene; 2019 Feb; 38(9):1398-1409. PubMed ID: 30302022
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Identification of 2(1H)-pyrimidinones as potential EGFR T790M inhibitors for the treatment of gefitinib-resistant non-small cell lung cancer.
    Huang J; Huang J; Wang N; Wang L; Li L; Wang C; Sun X; Li Y; Huang G; Ma X
    Bioorg Chem; 2019 Aug; 89():102994. PubMed ID: 31185393
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Cell-penetrating peptides containing the progesterone receptor polyproline domain inhibits EGF signaling and cell proliferation in lung cancer cells.
    Kaewjanthong P; Sooksai S; Sasano H; Hutvagner G; Bajan S; McGowan E; Boonyaratanakornkit V
    PLoS One; 2022; 17(3):e0264717. PubMed ID: 35235599
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Addition of S-1 to the epidermal growth factor receptor inhibitor gefitinib overcomes gefitinib resistance in non-small cell lung cancer cell lines with MET amplification.
    Okabe T; Okamoto I; Tsukioka S; Uchida J; Hatashita E; Yamada Y; Yoshida T; Nishio K; Fukuoka M; Jänne PA; Nakagawa K
    Clin Cancer Res; 2009 Feb; 15(3):907-13. PubMed ID: 19188161
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Long non-coding RNA BC087858 induces non-T790M mutation acquired resistance to EGFR-TKIs by activating PI3K/AKT and MEK/ERK pathways and EMT in non-small-cell lung cancer.
    Pan H; Jiang T; Cheng N; Wang Q; Ren S; Li X; Zhao C; Zhang L; Cai W; Zhou C
    Oncotarget; 2016 Aug; 7(31):49948-49960. PubMed ID: 27409677
    [TBL] [Abstract][Full Text] [Related]  

  • 37. miR-762 activation confers acquired resistance to gefitinib in non-small cell lung cancer.
    Ge P; Cao L; Chen X; Jing R; Yue W
    BMC Cancer; 2019 Dec; 19(1):1203. PubMed ID: 31823748
    [TBL] [Abstract][Full Text] [Related]  

  • 38. [A review: drug-drug interactions of epithelial growth factor receptor-tyrosine kinase inhibitors].
    Zhong J; Wang J
    Zhonghua Zhong Liu Za Zhi; 2022 Jul; 44(7):717-724. PubMed ID: 35880337
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Ferumoxytol and CpG oligodeoxynucleotide 2395 synergistically enhance antitumor activity of macrophages against NSCLC with EGFR
    Wang G; Zhao J; Zhang M; Wang Q; Chen B; Hou Y; Lu K
    Int J Nanomedicine; 2019; 14():4503-4515. PubMed ID: 31417255
    [No Abstract]   [Full Text] [Related]  

  • 40. Fighting cancer drug resistance: Opportunities and challenges for mutation-specific EGFR inhibitors.
    Juchum M; Günther M; Laufer SA
    Drug Resist Updat; 2015 May; 20():12-28. PubMed ID: 26021435
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.